Gilead acquired global rights to an oral oncology candidate from China‑based Genhouse Bio, paying $80 million up front. The deal gives Gilead an additional small‑molecule option in its cancer pipeline and grants Genhouse capital and partner‑scale development resources as it pursues an IPO in Hong Kong. Gilead’s purchase reflects continued western biopharma interest in China‑originated candidates and the strategic use of asset buys to accelerate portfolio expansion in oncology.